- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00266279
Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
Phase II Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The optimal dose and schedule for the combined treatment with oxaliplatin and capecitabine have not been defined. The aim of this Phase II study is to determine the response rate of combined oxaliplatin and capecitabine treatment at a given dose and schedule in patients with Head and Neck cancer for which there is no curative treatment.
The study also aims to determine the qualitative and quantitative toxicity and reversibility of toxicity of the above combination and to evaluate any changes in performance status, quality of life, overall survival and progression-free survival.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- University of Louisville, James Graham Brown Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed squamous cell cancer of Head and Neck
- Patients must have metastatic or locally recurrent disease
- Patients must have disease not curable by surgery as estimated by one of the protocol investigators, and should not be eligible for reradiation protocol or have failed reradiation protocol.
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan
- Age >18 years of age
- Life expectancy of greater than 12 weeks
- ECOG performance status 0, 1 or 2 (Karnofsky >50%; see Appendix B)
Patients must have adequate bone marrow function as defined below:
- absolute neutrophil count > 1,500
- platelets > 100,000
- hemoglobin > 8 g/dl
Patients must have adequate renal function as defined by a creatinine clearance >30 mL/min (measured or estimated by the Cockroft and Gault equation)
- Cockroft and Gault equation:
- Creatinine clearance for males =(140-age[yrs])(body wt[kg])/72(serum creatinine[mg/dL])
- Creatinine clearance for females = 0.85 x male value
Patients must have adequate liver function as defined below:
- total bilirubin 1.5x upper limit of normal
- albumin > 2.5 g/dl
- AST(SGOT) and ALT(SGPT) and Alkaline Phosphatase must be < 5 times upper limit of normal
- Patients could have received 1 or 2 previous chemotherapy regimens prior to entering the study. Patients must have recovered from acute toxicities from chemotherapy or radiotherapy administered prior to entering this study. Alopecia may not be resolved and peripheral neuropathy (grade 1) may be present.
- Patients with reproductive potential must use an adequate contraceptive method (e.g., abstinence, intrauterine device, oral contraceptives, barrier device with spermicide or surgical sterilization) during treatment and for three months after completing treatment.
- Ability to understand and willingness to sign a written informed consent document
Exclusion Criteria:
- Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-fluorouracil or oxaliplatin
- Patients who have had chemotherapy or radiotherapy within 4 weeks prior to first treatment in this study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- Patients receiving any other investigational agent(s)
- Patients with symptomatic brain metastases or actively receiving any therapy for brain metastasis (because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events)
- Active second malignancy in the last 5 years except for non-melanoma skin cancer or carcinoma-in-situ
- Clinically significant cardiac disease (e.g. congestive heart failure, New York Heart Association Class II or greater, symptomatic coronary artery disease and cardiac arrhythmias) or myocardial infarction within the last 12 months.
- If patient is unable to swallow, xeloda may be crushed per hospital policy/procedure. See attached Appendix G.
- Patients who have had an organ allograft.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnancy
- Known Hepatitis B , Hepatitis C, HIV
Inclusion of Minorities:
Members of all ethnic groups are eligible for this trial.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Treatment with Study Drugs
Treatment with combination of oxaliplatin and capecitabine using study dose and schedule.
|
Agent, DOSE AND SCHEDULE (28-days cycle): Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21 |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Overall Response Rate
Zeitfenster: Every two 28 day treatment cycles until subject no longer on treatment due to disease progression
|
Among the 15 patients treated, 2 (13%) achieved partial response (PR), and 5 (33%) achieved stable disease (SD), for a Overall Response Rate (ORR) of 46% measured by RECIST criteria. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. Overall Response Rate (ORR)=PR+CR. |
Every two 28 day treatment cycles until subject no longer on treatment due to disease progression
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Qualitative and Quantitative Toxicity
Zeitfenster: At study enrollment, Every two 28 day treatment cycles, and at end of treatment due to disease progression
|
Number of patients that developed common side effect of diarrhea.
|
At study enrollment, Every two 28 day treatment cycles, and at end of treatment due to disease progression
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Damian Laber, M.D., University of Louisville, James Graham Brown Cancer Center
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 153.05
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Oxaliplatin, Capecitabine
-
Hebei Medical UniversityAbgeschlossenAdenokarzinom des gastroösophagealen ÜbergangesChina
-
AIO-Studien-gGmbHiOMEDICO AGBeendetKolorektale NeubildungenDeutschland
-
Samsung Medical CenterAbgeschlossen
-
Hebei Medical UniversityUnbekanntAdenokarzinom des gastroösophagealen ÜbergangesChina
-
Peking UniversityTaiho Pharmaceutical Co., Ltd.UnbekanntFortgeschrittenes MagenkarzinomChina
-
Hebei Medical UniversityUnbekanntMagenkrebs | LebermetastasenChina
-
Northwestern UniversityAbgeschlossenSpeiseröhrenkrebsVereinigte Staaten
-
Swiss Group for Clinical Cancer ResearchAbgeschlossen
-
Seoul National University HospitalNational Cancer Center, Korea; Chonbuk National University Hospital; Chonnam National... und andere MitarbeiterAbgeschlossenMagenneoplasmen | Krebs des Lymphknotens
-
Hebei Medical UniversityUnbekanntLebermetastasen | HER-2-positiver MagenkrebsChina